Why undergoing this examination?

Alzheimer’s Disease (AD) is a progressive and irreversible neurological disease characterized by cognitive deterioration and behavioral disorders. AD can be classified based on age and onset (before or after 55-60 years old) into early or late onset, or based on the absence or presence of familial segregation. The most common form is late onset, with or without family aggregation, occurring in approximately 90% of cases. Between 30-40% of late-onset cases show familial aggregation. A family member affected by AD constitutes a significant risk factor in the development of the disease. AD is a complex alteration involving multiple factors, including genetic factors. Therefore, a genetic analysis can contribute to early diagnosis and improved patient quality of life. 

What is this exam?

The ADGen Exam is a genetic profile that analyzes four genes (APP, PSEN1, PSEN2, and APOE) related to the development of Alzheimer’s disease, enabling early diagnosis. These genes and their analyzed variants have been widely recognized in various databases and scientific publications. The analysis is performed through different DNA amplification and sequencing techniques. 

For whom is it indicated?

• Patients with a family history of AD. 
• Patients with mild or moderate cognitive impairments who want to determine their genetic risk. 
• Asymptomatic patients who want to determine their genetic risk. 

Technology

Sanger Sequencing